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with compromised renal function, and meticulous tech-
nique in the performance of the procedure.
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INVITED COMMENTARY
Timothy M. Sullivan, MD, Rochester, Minn
The article by Kashyap et al helps define outcomes for renal
intervention in the presence of renal insufficiency, a cohort previ-
ously defined as high risk for surgical therapy. Hallett et al1
evaluated 402 patients having surgical renal revascularization with
preoperative serum creatinine values 2 mg/dL. Perioperative
mortality was 15%, and a substantial number went on to hemodi-
alysis, including nearly one third of patients whose baseline serum
creatinine was 3 mg/dL.
The current data provide a baseline for expected results after
intervention in the face of renal insufficiency (as do the Hallett et al
data for surgical repair), but they also raise a number of questions.
Why did renal function not improve more after intervention?
Although many patients did respond, mean serum creatinine was
2.2 mg/dL at baseline and 2.4 mg/dL at 1 year; clearly these
patients, in general, continued to have deteriorating renal function
over time that was not halted by endovascular intervention.
Although the authors define success as either stabilization or
improvement (which seems entirely reasonable), when looked at in
another light, 72 (58%) of 125 patients did not improve—they
were not responders—a sobering statistic. Rapid decline in renal
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function before intervention was associated with a favorable re-
sponse; unfortunately, this represents a very small group of patients
in most practices. When responders were compared with nonre-
sponders, no preoperative clinical or demographic factor was asso-
ciated with improvement in glomerular filtration rate after inter-
vention, including preoperative serum creatinine level. The problem
may lie with the presence of atheromatous embolization, and its
solution may be distal embolic protection.
Little is known about the incidence of atheromatous emboli-
zation during visceral intervention. Krishnamurthi et al2 per-
formed kidney biopsies in 44 patients having surgical renal
revascularization and found that 36% had evidence of athero-
embolization. We should expect, then, that many patients already
have damaged kidneys from this phenomenon and that many will
sustain further insult from the interventional procedure itself, even
when performed with impeccable technique. Atheroembolization
may be clinically silent in patients with normal kidney function, but
it might tip the balance toward further deterioration in those with
baseline dysfunction.
Holden et al3 used embolic protection during renal stenting in
63 patients with renal insufficiency and 60% of filters contained
debris. At 16 months of mean follow-up, 94% of patients had
stabilization or improvement in renal function, substantially better
than the results reported in most series. Edwards et al4 used distal
balloon occlusion as an adjunct to renal intervention in 26 patients
with renal insufficiency and found that short-term results ap-
proached those for surgical revascularization, with statistically sig-
nificant improvement in postprocedure renal function. Data from
these two studies, albeit in relatively small groups of patients,
suggest that the use of embolic protection is of benefit, especially in
those with pre-existing renal dysfunction.
No protection systems are currently approved for noncarotid
use. The Cardiovascular Outcomes in Renal Atherosclerotic Le-
sions (CORAL) trial5 will likely yield important information about
which groups of patients benefit from intervention and the impact
of embolic protection. Until these data are available, it seems
reasonable to consider the use of embolic protection, especially in
patients with pre-existing renal dysfunction and for those with
hostile aortas. Future trials of protection systems for renal use are
confounded by the current requirement that they be paired with an
approved renal stent, an issue that will require continuing dialogue
with the US Food and Drug Administration.
As clinicians, our ultimate goal is to prevent the onset of
dialysis-dependent renal failure in this difficult group of patients.
Even with a highly skilled group of operators, 17 of 125 patients in
this series went on to dialysis, including nearly 10% of responders
and nearly 40% of nonresponders. Clearly, there are patients in
whom we are doing more harm than good. The authors are to be
congratulated for presenting their results in this challenging pa-
tient population. Their study, however, raises many questions
about patient selection, expected results, and the optimal tech-
nique for renal intervention.
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